Royce & Associates LP Has $10.03 Million Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Royce & Associates LP lifted its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 7.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 691,455 shares of the company's stock after buying an additional 45,755 shares during the quarter. Royce & Associates LP owned approximately 0.71% of ARS Pharmaceuticals worth $10,026,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. RA Capital Management L.P. lifted its holdings in ARS Pharmaceuticals by 14.8% in the first quarter. RA Capital Management L.P. now owns 10,860,977 shares of the company's stock worth $110,999,000 after acquiring an additional 1,401,299 shares during the last quarter. Vanguard Group Inc. raised its position in shares of ARS Pharmaceuticals by 37.0% during the 1st quarter. Vanguard Group Inc. now owns 2,886,455 shares of the company's stock worth $29,500,000 after purchasing an additional 779,969 shares during the period. Jacobs Levy Equity Management Inc. lifted its holdings in shares of ARS Pharmaceuticals by 1,280.5% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 277,706 shares of the company's stock worth $2,838,000 after purchasing an additional 257,589 shares during the last quarter. Raymond James & Associates acquired a new position in ARS Pharmaceuticals during the 3rd quarter valued at approximately $2,969,000. Finally, Allspring Global Investments Holdings LLC bought a new position in ARS Pharmaceuticals during the 3rd quarter worth $2,584,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, CEO Richard E. Lowenthal sold 100,000 shares of the company's stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $12.93, for a total value of $1,293,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,398,499 shares of the company's stock, valued at approximately $18,082,592.07. This represents a 6.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn sold 528,456 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $18.04, for a total transaction of $9,533,346.24. Following the completion of the transaction, the insider now directly owns 5,274,735 shares in the company, valued at $95,156,219.40. This represents a 9.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,584,351 shares of company stock valued at $24,152,378. Company insiders own 40.10% of the company's stock.

Wall Street Analysts Forecast Growth

SPRY has been the topic of a number of recent research reports. William Blair upgraded ARS Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. Raymond James upgraded shares of ARS Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and lifted their price objective for the company from $18.00 to $22.00 in a research report on Tuesday, August 13th. Leerink Partners boosted their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an "outperform" rating in a research note on Friday, September 20th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, ARS Pharmaceuticals presently has an average rating of "Buy" and an average price target of $24.00.

ARS Pharmaceuticals Stock Down 0.7 %

Shares of NASDAQ SPRY opened at $14.01 on Friday. The stock has a market cap of $1.36 billion, a P/E ratio of -27.47 and a beta of 0.90. The firm's 50-day simple moving average is $14.63 and its 200 day simple moving average is $11.73. ARS Pharmaceuticals, Inc. has a fifty-two week low of $4.28 and a fifty-two week high of $18.51.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.